Generation and validation of anti‐TREM2 agonistic antibodies to enable the advancement of drug targets in the TREM2/DAP12 signaling pathway for the treatment of Alzheimer Disease

Mustapha Moussaif, June Javens‐Wolfe, Alan D. Palkowitz, Timothy I. Richardson · 2025

Read Generation and validation of anti‐TREM2 agonistic antibodies to enable the advancement of drug targets in the TREM2/DAP12 signaling pathway for the treatment of Alzheimer Disease by Mustapha Moussaif, June Javens‐Wolfe, Alan D. Palkowitz, Timothy I. Richardson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712616.txt.

Description

Mustapha Moussaif and co-authors build and check antibodies that switch on a brain immune receptor in this 2025 paper. The receptor, TREM2, helps microglia clear debris in the brain, and its signaling is tied to Alzheimer disease. Drug hunters lacked well-tested, openly shared tools to probe the pathway. The team rebuilt candidate antibodies from published and patent sequences.

They made the antibodies in several formats, including one meant to cross into the brain. Tests in cells measured whether the antibodies fired the pathway's signals. One candidate, AL2p31, bound human but not mouse TREM2 and triggered the key signal cleanly. The validated tools are meant to speed target testing for Alzheimer drug programs.

Catalog record

CREATORMustapha Moussaif, June Javens‐Wolfe, Alan D. Palkowitz, Timothy I. Richardson
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712616

Browse the full library · About the Tower of Babel